Argenx posts Q3 2026 sales of $1.7 billion, 54% YoY growth, and outlines 2027 launch pipeline
Argenx reported third‑quarter 2026 product net sales of $1.7 billion, a 54% year‑over‑year increase driven by VYVGART. Net income was $506 million and earnings per share were $7.80. The company said Phase 3 data for empasiprubart are expected in December 2026 and that FB102 will move to Phase 3 in celiac disease, while it plans to file an sBLA for VYVGART Hytrulo in IMNM by year‑end. It also highlighted a $2.2 billion acquisition of Forte Biosciences that raises 2026 R&D and SG&A spending to about $4 billion.
Why it matters
The sales surge confirms strong demand for VYVGART, supporting revenue growth expectations for 2027. However, higher operating costs from the Forte deal and the $4 billion expense outlook compress margins, meaning investors should watch expense trends and upcoming data readouts for empasiprubart and FB102.
Key facts
- 1Product net sales were $1.7 billion in Q3 2026, up 54% year‑over‑year. stocktitan.net
- 2Net income was $506 million in Q3 2026. stocktitan.net
- 3Earnings per share were $7.80 in Q3 2026. seekingalpha.com
- 4Phase 3 data for empasiprubart are expected in December 2026. stocktitan.net
- 5FB102 will advance to Phase 3 in celiac disease. stocktitan.net
- 6The company plans to submit an sBLA for VYVGART Hytrulo in IMNM by year‑end 2026. stocktitan.net
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.